I am a senior research leader with extensive experience in cancer biology and translational oncology, currently focusing on the molecular mechanisms driving therapy resistance in non-small cell lung cancer (NSCLC). Over the course of my career, I have led interdisciplinary teams, integrating genomics, transcriptomics, epigenomics, metabolomics, and functional genomics to uncover novel therapeutic targets and biomarkers. My research emphasizes a mechanistic understanding of tumor evolution, heterogeneity, and metabolic adaptation, aiming to translate molecular insights into strategies that improve patient outcomes.
I have a strong track record of successfully managing complex projects, securing competitive funding, and mentoring emerging scientists, fostering a collaborative and innovative research environment. My leadership style is grounded in scientific rigor, strategic vision, and a commitment to excellence. I am passionate about leveraging cutting-edge technologies and integrative approaches to address critical challenges in cancer biology, while advancing precision medicine and translational research.
I am particularly motivated by the opportunity to bridge fundamental discoveries with therapeutic applications, guiding my team to push the boundaries of knowledge and impact the field of oncology at both a scientific and clinical level.
Research Activities
Genome-wide association studies (GWAS) for the identification of germline variants associated with diseases, other binary phenotypes and quantitative traits.
Genome assembly of high resolution, haplotype resolved genomes and polymorphism characterization
Exploring the genetic and epigenetic background underlying phenotype’s variability
Analysis of chromatin remodeling and epigenetic changes in different biological states
Transcriptomic analysis of cancer cells, stem cells, organoids, human and murine tissues in disease models
Transcriptomic profiling for coding and non-coding RNAs biomarker discovery and regulatory pathway analysis

















